Molina Healthcare Inc (MOH)

Molina Healthcare stock maintained its position near $200 on August 31, 2026, following its July 22 earnings report which surpassed analyst expectations for both EPS and revenue. Despite beating estimates, the company experienced a year-over-year revenue decline of 4.8% and a negative net margin. The stock currently trades in the middle of its 52-week range, with analysts anticipating $5.29 EPS for the full year.

Molina Healthcare's stock is trading near its analyst consensus price target following a weak Q2 2026 earnings report and cautious full-year guidance. The company experienced a decline in revenue and a sharp drop in adjusted earnings per share due to higher medical costs and customer losses. Analysts have revised down their earnings estimates, viewing the stock as fairly valued despite its premium valuation compared to industry averages.

Molina Healthcare's stock is trading near Wall Street's consensus price target, supported by strong Q2 2026 earnings and institutional inflows. Despite a premium valuation and medical cost pressures, the company's robust cash generation, efficiency gains, and strategic contract renewals in government-sponsored programs (Medicaid, Medicare, Marketplace) are reinforcing investor confidence. The stock's performance hinges on continued disciplined medical cost management and execution of its growth strategy.

Molina Healthcare insiders have sold US$3.6 million worth of stock over the last year, with no insider purchases recorded. This selling activity, particularly by President and CEO Joseph Zubretsky, could suggest that insiders believe the stock is fully valued or may face future headwinds. While insider selling isn't always a negative indicator, a significant amount without corresponding buying often warrants attention from potential investors.

Molina Healthcare reported strong Q1 2025 earnings, surpassing analyst expectations with adjusted EPS of $6.08 and revenue of $11.15 billion, driven by new contract wins and acquisitions. The company reaffirmed its full-year 2025 guidance and expressed confidence in achieving its long-term adjusted EPS growth target of 13% to 15%, fueled by embedded earnings from newly awarded contracts and recent acquisitions. Key drivers included significant growth in premium revenue and Marketplace membership, alongside disciplined medical cost management.